Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;16(6):479-490.
doi: 10.2217/pme-2018-0077. Epub 2019 Oct 24.

Genetic variants of nucleotide excision repair pathway and outcomes of induction therapy in acute myeloid leukemia

Zohreh Sharifi  1 , Mohammad Faranoush  2 , Alireza Mohseni  3 , Shahrbano Rostami  4 , Mani Ramzi  5 , Mohammad J Sharifi  1   6
Affiliations

Genetic variants of nucleotide excision repair pathway and outcomes of induction therapy in acute myeloid leukemia

Zohreh Sharifi et al. Per Med. 2019 Nov.

Abstract

Aim: Acute myeloid leukemia (AML) is a heterogeneous disease in pathogenesis and response to therapy. Nucleotide excision repair (NER) pathway has a major role in the elimination of genotoxic effects of chemotherapeutic agents. We aimed to clarify the effects of selected variants of XPD, XPC, ERCC5 and ERCC1 genes on the outcomes of induction therapy. Materials & methods: The prevalence of NER genetic variants was evaluated in 67 subjects with AML and their effects on clinical outcomes were analyzed by χ2 test. Results: The XPD 751 Lys variant was associated with improved response to chemotherapy compared with XPD 751 Gln and Lys/Gln variants (p = 0.023; odds ratio: 4.5; 95% CI: 1.14-17.73). There were no associations between other genotypes and any outcomes. Conclusion: Current findings suggest that XPD Lys751Gln variant could be considered as a prognostic factor in AML.

Keywords: AML; NER; XPD; complete remission; induction therapy; toxicity.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This work was supported by Iranian Blood Transfusion Organization (IBTO). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

    1. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet 381(9865), 484–495 (2013). - PubMed
    1. Li X, Gong J, Feldman E, Seiter K, Traganos F, Darzynkiewicz Z. Apoptotic cell death during treatment of leukemias. Leuk. Lymphoma. 13(Suppl. 1), 65–70 (1994). - PubMed
    1. Crook TR, Souhami RL, McLean AE. Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Cancer Res. 46(10), 5029–5034 (1986). - PubMed
    1. Kellner U, Rudolph P, Parwaresch R. Human DNA-topoisomerases – diagnostic and therapeutic implications for cancer. Onkologie 23(5), 424–430 (2000). - PubMed
    1. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 22(56), 9063–9074 (2003). - PubMed

Publication types

MeSH terms